Phase 2a RCT: Vaccine efficacy in adults in a respiratory syncytial virus challenge study.

Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study -New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Challenge Study Shows Efficacy of RSV Vaccine in Healthy Adults – HealthDay

Commentary on Twitter

A human challenge model was used to assess the safety and immunogenicity of an RSV prefusion F protein-based vaccine against RSV infection. The vaccine construct has advanced to further clinical testing.https://t.co/KKfqzCyyGF pic.twitter.com/H7i7F8KLmv

— NEJM (@NEJM) June 22, 2022